What is Micell Technologies?
Micell Technologies operates at the intersection of advanced material science and interventional cardiology. The company specializes in the development of drug-eluting stents that leverage supercritical fluid technology to optimize drug delivery and improve patient outcomes. By mitigating the limitations inherent in traditional coating processes, Micell provides a sophisticated alternative for treating cardiovascular disease. Its flagship offering, the MiStent SES, currently holds a CE mark, facilitating its distribution across international markets through strategic partnerships. While the company maintains a robust presence in Europe and other global regions, it remains focused on refining its technological edge to address the evolving needs of the medical device industry.
How much funding has Micell Technologies raised?
Micell Technologies has raised a total of $119.3M across 4 funding rounds:
Private Equity
$25.8M
Multiple Rounds
$93.5M
Private Equity (2016): $25.8M, investors not publicly disclosed
Private Equity (2017): $31.8M, investors not publicly disclosed
Private Equity (2017): $41.8M, investors not publicly disclosed
Private Equity (2017): $20M, investors not publicly disclosed
Key Investors in Micell Technologies
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Micell Technologies?
With the recent influx of capital, Micell Technologies is well-positioned to accelerate its strategic roadmap. The primary focus remains the expansion of its commercial footprint for the MiStent SES, alongside the potential exploration of new clinical indications for its supercritical fluid platform. As the company navigates the complexities of the interventional cardiology market, the integration of this latest financing will likely support enhanced manufacturing capabilities and the pursuit of regulatory milestones in additional territories. Investors and industry observers will be monitoring the company's ability to leverage this liquidity to maintain its competitive advantage against established incumbents in the drug-eluting stent space.
See full Micell Technologies company page
